Advancing Chiral Chemistry in API Synthesis - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Advancing Chiral Chemistry in API Synthesis
Functionalized supramolecular catalysts and an enantioselective route to unnatural amino acids are some recent developments.

Pharmaceutical Technology
Volume 33, Issue 11, pp. 44-50

Biocatalysis at work

An example of a successful process substitution using biocatalysis was recently reported for producing an intermediate used in the synthesis of aliskiren, a renin inhibitor used to treat hypertension. A key step in the synthesis of aliskiren is an enzymatic resolution catalyzed by pig-liver esterase (PLE). PLE is a versatile biocatalyst because it has a broad substrate spectrum and excellent enantio- and regio-selectivity. Commercially available PLE is animal derived, which can result in variability. To address this problem, DSM (Heerleen, The Netherlands) and its collaboration partner, the Graz University of Technology in Austria, identified different isoforms of PLE. Using capabilities in enzyme development and production, a highly efficient and patented microbial expression system and fermentation process was developed for different isoforms of PLE that runs at a 25,000-L scale at DSM. This system delivers nonanimal-derived PLE isoforms (PharmaPLEs, DSM) at a large scale for pharmaceutical applications (13).

In another development, researchers at Merck & Co. (Whitehouse Station, NJ) reported on the pilot-scale asymmetric synthesis of 4,4-dimethoxytetrahydro-2H-pyran-3-ol with a ketone reductase and in situ cofactor recycling using glucose dehydrogenase in high yield and enantiomeric excess (11, 12).

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,


1. D. Uraguchi, Y. Ueki, and T. Ooi, Science 326 (5949), 120–123 (2009).

2. S.J. Zuend et al., Nature 461 (7266), 968–970 (2009).

3. Y. Lu, T.C. Johnstone, and B.A. Arndtsen, J. Am. Chem. Soc. 131 (32), 11284–11285 (2009).

4. M. Penner et al., J. Am. Chem. Soc. 131 (40), 14216–14217 (2009).

5. P. Van Arnum, Pharm. Technol. 32 (9), 60–64 (2008).

6. E. Balskus and E. Jacobsen, Science 317 (5845), 1736–1740 (2007.)

7. J. Kim, J.A. Ashenhurst, and M. Movassaghi, Science 324 (5950), 238–241 (2009).

8. J. E. Wilson, A.D. Caserez, and D.W.C. MacMillan, J. Am. Chem. Soc. 131 (32), 113332–11334 (2009).

9. P. Van Arnum, Sourcing and Management, July 8, 2009,

10. T.V. RajanBabu et al., J. Am. Chem. Soc., 130 (25), 7845–7847 (2008).

11. P. Van Arnum, Sourcing and Management, Sept. 1, 2009,

12. I. Andrews et al., Org. Process Res. Dev. 13 (3), 397–408 (2009).

13. P. Van Arnum, Pharm. Technol. 33 (9) API Synthesis and Formulation suppl. s34–s38 (2009).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here